According to the latest report by IMARC Group, titled “Jet Lag Therapy Market by Product (Prescription Drugs, Melatonin, Herbal and Natural Products, Medical Devices, and Others), Application (Business Travelers, Cabin Crew, Athletes, Seasonal Travelers, and Others), Distribution Channel (Over the Counter, Online), End Users (Hospitals, Homecare, Speciality Clinics, and Others), and Region 2024-2032,” the global jet lag therapy market size reached US$ 424.8 Million in 2023. Jet lag is a temporary sleep disorder that occurs when individuals travel across multiple time zones. It disrupts the body's internal circadian rhythm, leading to symptoms such as fatigue, insomnia, disorientation, and impaired cognitive function. Jet lag therapy refers to a range of treatments and strategies aimed at mitigating the symptoms and effects of jet lag. It focuses on helping travelers adjust to new time zones more effectively and minimize the impact of disrupted sleep patterns. It encompasses various approaches, including light therapy, melatonin supplementation, sleep aids, and lifestyle adjustments.
Global Jet Lag Therapy Market Trends:
The rising international travel, fueled by globalization and increased business and leisure activities, represents the key factor propelling the market growth. Business professionals, frequent flyers, and tourists alike are seeking ways to minimize the negative effects of jet lag, thereby driving the demand for innovative therapies and products. In line with this, the growing focus on health and wellness among individuals is positively influencing the market growth. Consumers are increasingly seeking therapies that promote relaxation, improve sleep, and enhance cognitive performance due to the rising health consciousness and the importance of maintaining overall well-being. Apart from this, the emergence of non-pharmacological and natural therapies, such as light therapy, mindfulness techniques, herbal supplements, and lifestyle adjustments, are providing an impetus to the market growth. Besides this, advancements in technology and research, increasing expenditure capacities of consumers, and growing collaborations between airlines and jet lag therapy providers, are presenting remunerative growth opportunities for the market. Looking forward, the market value is projected to reach US$ 602.6 Million by 2032, expanding at a CAGR of 3.84% during 2024-2032.
Market Summary:
- Based on the product, the market has been segmented as prescription drugs (provigil/nuvigil, ambien, lunesta, sonata, and others), melatonin, herbal and natural products, medical devices (light box and wearable devices), and others. According to the report, melatonin represents the largest segment.
- On the basis of the application, the market has been divided into business travelers, cabin crew, athletes, seasonal travelers, and others. Currently, business travelers account for the largest market share.
- Based on the distribution channel, the market has been bifurcated into over the counter and online. According to the report, over the counter represents the largest segment.
- On the basis of the end users, the market has been categorized into hospitals, homecare, specialty clinics, and others. Currently, specialty clinics account for the largest market share.
- Region-wise, the market has been segmented into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America is the largest market for jet lag therapy.
- The competitive landscape of the market has also been examined, with some of the key players being Chrono Eyewear B.V., Clinigen Limited, Jamieson Wellness Inc., Lucimed SA, Lumie, Nature Bright, Nature's Bounty Inc. (Nestlé S.A.), Northern Light Technologies, Re-Timer Pty Ltd., Verilux Inc. etc.
Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Million |
Products Covered |
- Prescription Drugs: Provigil/Nuvigil, Ambien, Lunesta, Sonata, Others
- Melatonin
- Herbal and Natural Products
- Medical Devices: Light Box, Wearable Devices
- Others
|
Applications Covered |
Business Travelers, Cabin Crew, Athletes, Seasonal Travelers, Others |
Distribution Channels Covered |
Over the Counter, Online |
End Users Covered |
Hospitals, Homecare, Speciality Clinics, Others |
Regions Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Chrono Eyewear B.V., Clinigen Limited, Jamieson Wellness Inc., Lucimed SA, Lumie, Nature Bright, Nature's Bounty Inc. (Nestlé S.A.), Northern Light Technologies, Re-Timer Pty Ltd., Verilux Inc. etc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800